Sequana Medical
Post in 2024
Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.
FlixBus
Private Equity Round in 2024
FlixBus, operated by FlixMobility, is a notable provider of intercity travel, focusing on affordable, convenient, and environmentally-friendly transportation solutions. Since its inception in 2013, the company has established Europe's largest long-distance bus network and introduced green long-distance trains in 2018, alongside a pilot for all-electric buses in Germany and France. The platform offers travelers a sustainable alternative to private transportation, featuring amenities such as free WiFi, flexible online booking, and innovative ticketing systems. FlixBus also expanded its services to the United States in 2018, bringing its unique travel model to a broader audience. By collaborating with regional bus partners and private train companies, FlixMobility combines technological innovation with traditional transportation expertise, positioning itself as a leader in the evolving mobility landscape. As a result, FlixBus has transformed the travel experience for over 100 million people across Europe and the United States while contributing to job creation in the mobility sector.
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
IntegrityNext
Venture Round in 2023
IntegrityNext is a Munich-based company founded in 2016 by Martin Berr-Sorokin that specializes in supply chain compliance and sustainability monitoring. The company offers a cloud-based platform that enables businesses to oversee their suppliers' compliance with regulatory requirements, thereby reducing risk. Its platform automates the collection of supplier self-assessments and certificates, while also monitoring social media for potential malpractice and reputational threats. With features such as automated risk alerts, a pre-built supplier questionnaire, and a real-time dashboard, IntegrityNext assists small and medium-sized enterprises in translating complex compliance data requirements from international regulations into effective processes and systems. This comprehensive approach to supply chain compliance supports organizations in achieving greater transparency and accountability in their operations.
va-Q-tec
Acquisition in 2023
va-Q-tec is a high-tech company established in 2001, specializing in innovative insulation solutions, particularly through vacuum insulation panels (VIPs). The company's products are designed to enhance energy efficiency and are environmentally friendly, making them suitable for various applications. va-Q-tec's technology significantly reduces energy costs in diverse sectors, including the transportation of pharmaceutical products, refrigeration and freezing appliances, construction, and automotive and aerospace industries. The company operates through several segments, with a strong presence in Germany and across the European Union. Its customer base spans multiple industries, including healthcare, logistics, appliances and food, construction, and technical sectors.
Cardior Pharmaceuticals
Series B in 2021
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.
Deutsche Glasfaser
Acquisition in 2020
Deutsche Glasfaser Holding GmbH, founded in 2012 and based in Borken, Germany, specializes in the planning, construction, and operation of fiber optic networks aimed at rural and suburban areas. As a pioneering provider in the industry, the company focuses on delivering fiber-to-the-home (FTTH) connections to private households, businesses, and public institutions. By collaborating closely with municipalities, Deutsche Glasfaser aims to facilitate nationwide broadband expansion, contributing significantly to Germany's digital progress. The company is recognized for its innovative and cost-efficient approaches to fiber optic deployment, positioning itself as a technology leader in the market. With substantial backing from experienced investors, Deutsche Glasfaser has emerged as one of the strongest providers in Germany's telecommunications landscape.
SUSE is a global leader in open source solutions, providing reliable and enterprise-grade software to a diverse range of industries, including automotive, telecom, banking, healthcare, manufacturing, retail, and technology. With a strong focus on Enterprise Linux, Kubernetes Management, and Edge solutions, SUSE supports mission-critical workloads for over 60% of the Fortune 500 companies. The company emphasizes collaboration with partners and communities to empower customers to innovate across various environments, from data centers to the cloud and edge. SUSE offers consulting, blended services, and training and certification, primarily generating revenue from subscriptions. Headquartered in Nuremberg, Germany, SUSE employs nearly 2,000 people globally and derives a significant portion of its revenue from North America.
MediFox
Debt Financing in 2018
MediFox GmbH, founded in 1994 and headquartered in Hildesheim, Niedersachsen, Germany, specializes in developing software solutions for ambulatory nursing care service providers and nursing care homes. The company offers enterprise system software designed to support outpatient care services, inpatient facilities, and therapeutic practices. MediFox's software encompasses essential services such as resource and route planning, care and support documentation, management information systems, and administration services, including billing and factoring. By providing these tools, MediFox enables care providers to enhance their organizational structure and streamline their processes in response to evolving industry needs.
Simplify Medical
Series B in 2018
Simplify Medical, Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs intended for spinal use. Founded in 2013 and based in Sunnyvale, California, it offers innovative products such as the Simplify Disc, a non-metallic, MRI-compatible artificial cervical disc that preserves motion while allowing for full diagnostic imaging without the need for traditional CT scans. This technology minimizes patient exposure to ionizing radiation and is tailored for skeletally mature patients undergoing reconstruction at one level from C3 to C7 following discectomy procedures. Simplify Medical markets its products through distributors in the United Kingdom, Germany, and other international markets. The company was previously known as Simplify Delaware, Inc. before rebranding in February 2015.
Studienkreis
Venture Round in 2017
Studienkreis is one of Germany's largest providers of professional tutoring services, operating nearly 1,000 tuition schools nationwide since its establishment in 1974. The company specializes in providing offline and digital tutoring aimed at primary and secondary school students, offering support across all major subjects through its proprietary teaching materials and scientifically backed learning methodologies. Studienkreis focuses on helping children and adolescents enhance their academic performance and achieve consistently good grades. In addition to addressing specific academic queries, the company emphasizes fostering independent learning skills and a sense of responsibility in students, thereby improving their overall confidence in their educational journey.
Atricom and Le Büro
Private Equity Round in 2017
Two modern and strategically located office buildings in suburban Frankfurt.
Simplify Medical
Series B in 2017
Simplify Medical, Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs intended for spinal use. Founded in 2013 and based in Sunnyvale, California, it offers innovative products such as the Simplify Disc, a non-metallic, MRI-compatible artificial cervical disc that preserves motion while allowing for full diagnostic imaging without the need for traditional CT scans. This technology minimizes patient exposure to ionizing radiation and is tailored for skeletally mature patients undergoing reconstruction at one level from C3 to C7 following discectomy procedures. Simplify Medical markets its products through distributors in the United Kingdom, Germany, and other international markets. The company was previously known as Simplify Delaware, Inc. before rebranding in February 2015.
Cardior Pharmaceuticals
Series A in 2017
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.
GETEC is a prominent group of energy service providers operating across Germany and Europe, employing nearly 1,400 individuals. The company offers a comprehensive range of energy services in the liberalized energy market, focusing on energy efficiency, system design, and zero emissions. GETEC aims to guide clients through the complexities of the energy landscape by developing tailored solutions that extend beyond traditional energy considerations. Their approach emphasizes sustainability, efficiency, economic viability, and resource conservation, which are fundamental principles of their corporate philosophy. By providing integrated system solutions, GETEC creates added value for clients and supports them in improving their carbon footprint, with a commitment to future generations.
GlobalConnect
Acquisition in 2016
GlobalConnect is a prominent alternative provider of fiber network, data center, and managed hosting services in Northern Europe, primarily focusing on Denmark and Germany. Established in 1998 by Niels Zibrandtsen, the company operates a 12,500 km optical fiber network and manages approximately 13,000 square meters of data center space. GlobalConnect offers a range of services including bandwidth connectivity, colocation, and cloud infrastructure, catering to both enterprises and consumers. With a workforce of over 200 employees, the company is dedicated to delivering fast and reliable networking solutions, enhancing connectivity and technological capabilities for its clients across Sweden, Norway, Denmark, Finland, and Northern Germany.
GETEC is a prominent group of energy service providers operating across Germany and Europe, employing nearly 1,400 individuals. The company offers a comprehensive range of energy services in the liberalized energy market, focusing on energy efficiency, system design, and zero emissions. GETEC aims to guide clients through the complexities of the energy landscape by developing tailored solutions that extend beyond traditional energy considerations. Their approach emphasizes sustainability, efficiency, economic viability, and resource conservation, which are fundamental principles of their corporate philosophy. By providing integrated system solutions, GETEC creates added value for clients and supports them in improving their carbon footprint, with a commitment to future generations.
kfzteile24
Venture Round in 2016
kfzteile24 GmbH, established in 2001 and headquartered in Berlin, Germany, is a prominent retailer of automotive spare parts and accessories. The company operates primarily online via its platforms www.kfzteile24.de and www.autoteile24.de, offering a comprehensive range of products such as exhaust systems, axle suspension components, batteries, heaters, interior fittings, and braking systems at competitive prices. To complement its online distribution, kfzteile24 maintains three physical retail stores in Berlin, each with an affiliated repair shop for customer support. The company has experienced continuous growth since its founding, becoming one of Germany's largest online retailers for auto parts and accessories, with sales in the triple-digit million range.
Sequana Medical
Series C in 2015
Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.
kfzteile24
Acquisition in 2015
kfzteile24 GmbH, established in 2001 and headquartered in Berlin, Germany, is a prominent retailer of automotive spare parts and accessories. The company operates primarily online via its platforms www.kfzteile24.de and www.autoteile24.de, offering a comprehensive range of products such as exhaust systems, axle suspension components, batteries, heaters, interior fittings, and braking systems at competitive prices. To complement its online distribution, kfzteile24 maintains three physical retail stores in Berlin, each with an affiliated repair shop for customer support. The company has experienced continuous growth since its founding, becoming one of Germany's largest online retailers for auto parts and accessories, with sales in the triple-digit million range.
HusCompagniet
Acquisition in 2015
HusCompagniet A/S is a prominent house builder primarily operating in Denmark, with expanding activities in Sweden and Germany. The company specializes in the design, sale, and delivery of customizable single-family detached houses, which are largely constructed on-site on land owned by customers. Additionally, HusCompagniet offers semi-detached houses to both consumers and professional investors, and produces prefabricated wood-framed houses under the VårgårdaHus brand in Sweden. Headquartered in Horsens, Denmark, the company has established a strong market presence, being three times larger than its nearest competitor in Denmark. Since its incorporation in 2015, HusCompagniet has achieved significant revenue growth and has been recognized as House Builder of the Year in Denmark for three consecutive years, employing around 230 people and delivering over 1,000 houses annually across its markets.
Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.
Sequana Medical
Series C in 2014
Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.
Charleston Holding
Acquisition in 2014
Charleston Holding is an operator of nursing homes and residential care facilities in Germany, focused on serving physically and mentally impaired residents. The company adopts a buy-and-build strategy within the nursing home market, aiming to enhance its portfolio through acquisitions. Charleston provides a range of services, including nursing care, preventative care, and intensive care, along with assisted living and daycare options. By offering these services, Charleston Holding seeks to improve the quality of life for its residents and support their well-being into old age.
EEW Energy from Waste
Acquisition in 2013
EEW Energy from Waste GmbH is a German company specializing in waste incineration and the generation of energy from waste. Founded in 1873 and based in Helmstedt, it operates 37 modern plants across 19 locations, efficiently recycling approximately five million tons of waste annually. The company produces climate-neutral electricity, process steam, and district heating, serving around 500,000 households. EEW Energy from Waste is committed to environmentally friendly waste disposal and resource conservation, utilizing by-products such as slag for road construction. With a workforce of 1,300 employees, the company continually strives to enhance its processes and efficiency through research collaborations with universities. EEW Energy from Waste emphasizes safe waste disposal for local councils and businesses while providing innovative energy solutions designed for the future.
Vivoryon Therapeutics
Venture Round in 2012
Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.
Sapiens Steering Brain Stimulation
Series A in 2011
Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, Sapiens operates from offices in Eindhoven, the Netherlands, and Munich, Germany. The company is dedicated to developing a high-resolution, MRI-compatible DBS system designed to enhance patient comfort and improve therapeutic outcomes, particularly for individuals with Parkinson's disease. Sapiens’ innovative approach includes a unique steering brain stimulation system and image-guided programming, both of which are based on patented technologies.
United Digital Group
Acquisition in 2011
United Digital Group is a digital communication and marketing agency based in Hamburg, Germany, founded by Michael Riese in 1999. The company focuses on delivering comprehensive digitalization strategies and branding solutions to various industries, including finance, cosmetics, and jewelry. It offers a range of services, including consulting, analytics, business application redesign, brand management, and e-learning. Additionally, United Digital Group specializes in technology strategy, strategic planning, content production, affiliate marketing, dashboard development, channel planning, data analytics, and project management, positioning itself as a versatile partner for businesses seeking to enhance their digital presence and operational efficiency.
Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.
Activaero
Series A in 2011
Activaero GmbH is a drug delivery company specializing in controlled breathing technologies designed for the pulmonary delivery of inhaled therapeutic agents. Founded in 2004 and based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero develops innovative devices such as AKITA, which utilizes smart card technology for efficient drug delivery, and Watchhaler, specifically designed for children requiring inhaled medication. The company also offers AKITA², a technology for use in clinical trials, and LimiX, a flow limitation valve that regulates inhalation flow rates. In addition to its product offerings, Activaero provides measurement and diagnostic technologies for laboratory applications, including aerosol property measurement systems. Furthermore, the company engages in contract development and clinical trial logistics services, marketing its products through a network of distributors. Activaero's solutions aim to improve therapy outcomes for patients suffering from severe respiratory diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis.
AcadeMedia
Acquisition in 2010
AcadeMedia is the largest independent education provider in Northern Europe, offering a comprehensive range of educational services from pre-schools to adult education. The company operates approximately 550 units primarily in Sweden, Norway, and Germany. Its educational segments include preschools, compulsory schools, upper secondary schools, and adult education, with the upper secondary school segment generating the highest revenue. AcadeMedia's upper secondary school brands include Praktiska, Drottning Blanka, NTI, LBS, ProCivitas, and Rytmus. The majority of the company's revenue is derived from its operations in Sweden, reflecting its strong presence in the region's education sector.
Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.
Vivoryon Therapeutics
Series B in 2009
Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.
Sausalitos Holding
Private Equity Round in 2008
Sausalitos Holding GmbH, established in 1994 and headquartered in Munich, Germany, operates a chain of casual dining pubs. It specializes in offering a diverse range of food and drinks, with a focus on Californian-Mexican cuisine and unique gastronomic cocktails. The company is recognized as one of the leading leisure restaurant chains in Germany, providing dining options for breakfast, lunch, and dinner.
CBR is a fashion company based in Isernhagen, Germany, specializing in women's apparel. The company is known for its efficient business model, producing twelve collections annually for each of its labels. This approach allows CBR to provide its retail partners with a high speed of turnover and responsiveness to market trends. CBR operates both retail and outlet stores, as well as an online platform, enabling it to reach a broad customer base and offer a diverse range of fashionable clothing to women.
Pfaff Beteiligungs GmbH
Acquisition in 2006
Pfaff-silberblau's lifting and material handling business includes wire rope winches, chain hoists, rack and pinion jacks and hand pallet trucks. Its actuator business designs, develops, manufactures and markets components for lifting and motion control, including worm gear screw jacks, linear motion precision screws and quick lifting screw jacks. Based in Kissing, Germany, Pfaff-silberblau employs over 300 people and is represented worldwide through six international subsidiaries as well as numerous regional representatives.
U3 Pharma
Venture Round in 2006
U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Established in July 2001, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Professor Axel Ullrich. Since May 2008 U3 Pharma belongs to DAIICHI Sankyo Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide and no. 3 in Japan. Being part of this global environment, U3 Pharma is striving to provide patients around the world with innovative antibody-based therapeutics.
Metall Technologie Holding
Debt Financing in 2005
Metall Technologie Holding is a German manufacturer specializing in heat treatment industrial furnaces and related technologies. The company produces a variety of furnace types, including vacuum furnaces, continuous furnaces, atmosphere furnaces, and protective gas furnaces. Its products cater to diverse industries such as aeronautics, automotive, medical, steel manufacturing, and heat treatment contracting, serving clients globally. Metall Technologie Holding's furnaces are utilized for a wide range of applications, including gas and oil quenching, brazing of aluminum and stainless steel, sintering, metal injection molding, tempering, annealing, magnetic annealing and stabilization, aging and stress relieving, as well as low-pressure carburizing, nitriding, and cryogenic treatment.